United Therapeutics (UTHR) Stock May Be Undervalued Despite Its 132% Run

United Therapeutics has delivered a strong 5 year share performance, yet the current valuation checks still flag the stock as looking cheap on several measures. Recent regulatory milestones and pipeline progress now raise the question of whether the market is underestimating that profile or correctly pricing in the risks around execution and timelines.

• Over the past 5 years, United Therapeutics has returned 131.9%, which points to a stock that has already rewarded long term holders even before any further rerating.
• The FDA review processes for Tyvaso in idiopathic pulmonary fibrosis and ralinepag in pulmonary arterial hypertension can support sentiment on long term cash flow potential, while regulatory delays or less favourable outcomes remain a key risk for how much value investors ultimately ascribe to these therapies.
• On Simply Wall St’s broader checks, United Therapeutics earns a value score of 6 out of 6, which points to a stock that currently screens as undervalued on multiple traditional metrics.

The issue now is whether United Therapeutics’ recent pullback and strong value score together indicate a genuine margin of safety at today’s price or simply reflect the risks still embedded in the pipeline story.

Compare United Therapeutics’ pullback and high value score with other underappreciated opportunities by scanning 47 high quality undervalued stocks, which also combine stronger balance sheets with discounted valuations.

Is United Therapeutics a Bargain on Earnings?

P/E tends to suit United Therapeutics because the company is profitable and earnings are a key driver of how investors look at established biotechs. On this measure, United Therapeutics trades on a P/E of 16.0x, which is slightly below the wider biotech industry average of 17.0x and far below the broader peer group average of 58.0x. That already points to a stock that is not priced at a premium despite its established portfolio and late stage pipeline.

The Fair P/E ratio for United Therapeutics is 24.5x, based on a model that factors in the company’s margins, risk profile, size and sector. This is meaningfully higher than the current 16.0x, which implies a sizeable gap between what the model suggests investors might pay for these earnings and what the market currently applies. Despite recent FDA filing milestones for Tyvaso in idiopathic pulmonary fibrosis and ralinepag in pulmonary arterial hypertension, the P/E still sits at a discount to that tailored fair level.

On the P/E multiple alone, United Therapeutics stock appears undervalued relative to both its industry and its modelled fair ratio.

See what the numbers say about this price — find out in our valuation breakdown.

The United Therapeutics Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where United Therapeutics' valuation puzzle leaves off. They spell out which paths for future growth, margins and earnings would need to play out for the stock to be worth materially more or less than today’s price, and they sit on Simply Wall St’s Community page. Rather than focusing on a single multiple or model output, each one lays out its own assumptions so you can compare them with actual results over time.

One of the top community narratives on United Therapeutics: 10% undervalued

"Heavy dependence on a few core drugs heightens risk from patent expirations, increasing vulnerability to revenue declines and competition from generics."

Read one of the top narratives on United Therapeutics

Do you think there's more to the story for United Therapeutics? Head over to our Community to see what others are saying!

The Bottom Line

United Therapeutics screens as undervalued on earnings multiples, which points to a market that is cautious despite supportive valuation checks. The key question is whether discounted expectations reflect temporary skepticism or a fair response to the execution and concentration risks around its key therapies. For you as an investor, the crux is whether regulatory progress and future cash flows eventually prompt a re rating, or whether current concerns keep the P/E anchored where it is. That tension between a cheap multiple and a pipeline with clear execution hurdles is what now defines the risk reward trade off.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com